Tim Foley

Tim first obtained his BSc in cell biology and biochemistry and then a MSc in organic chemistry at the University of California - San Diego (UCSD). Still at UCSD, he pursued inhibitors of bacterial natural product biosynthesis and received his Ph.D. in chemistry in 2010. He conducted his post-doctoral studies at the National Center for Advancing Translational Sciences (NCATS) at the NIH from 2010 to 2014. In this position, he further developed his knowledge of enzymology and molecular pharmacology in the context of high throughput screening. Notably, he played a leading role in the discovery of ML267, a first in class inhibitor of bacterial phosphopantetheinyl transferase with potent in vitro antibacterial activity.

Tim joined Pfizer in February 2014 to support the Pfizer Centers for Therapeutic Innovation portfolio and the Serine Hydrolase Gene Family platform. He quickly became a leader in the Primary Pharmacology Group where he guides pharmacology assay design and execution for projects to support hit discovery and compound optimization into clinical candidates. Over the past year, Tim has been leading the organizational effort to develop hit identification capabilities with DNA-encoded library technologies.